Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $6.75 Consensus Target Price from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus recommendation of “Hold” from the eight research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.75.

Several brokerages have weighed in on INO. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th. Citigroup reissued a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, UBS Group reaffirmed an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the 1st quarter worth about $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $86,000. Bank of Montreal Can increased its stake in Inovio Pharmaceuticals by 23.7% in the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 11,110 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in Inovio Pharmaceuticals in the second quarter worth $35,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.63 on Friday. The company has a market cap of $108.77 million, a price-to-earnings ratio of -0.63 and a beta of 1.62. The stock’s fifty day moving average price is $1.86 and its two-hundred day moving average price is $2.03. Inovio Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. On average, equities analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.